Exclusive Summary

• This product has obtained US FDA GMP certification and is registered in the United States, possessing strong international market access qualifications and quality assurance.
• Nicardipine injection holds a crucial therapeutic position in various cardiovascular diseases such as hypertensive emergencies and crises, with stable and growing global market demand.
• As a generic version of the originator drug Cardene®, it offers significant cost advantages and market competitive potential after patent expiration.
• The current generic drug landscape is relatively stable, and high-quality US FDA GMP certification and USP pharmacopoeia compliance provide a differentiated competitive edge.
• This collaboration can provide a stable supply of high-quality generic drugs, meeting the overseas market's demand for cost-effective emergency cardiovascular treatment options.